Skip to main content

Fiscal Wizard · Single-issue tearsheet

ABBV / Aug 13, 2026 Run #13857

ABBV

AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Composite verdict

B 61.2 / 100
Bullish setup · Reversal 6 drivers · 2 gates blocking
  • Stochastic Cross
  • MA Rejection
  • Fibonacci Retracement
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 5th of 9 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 17 signals0% Bear
Momentum Bullish 82Mean-reversion Bullish 65

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $-1.85Earnings power value $30.43Price $248.76

Priced above its no-growth earnings power value ($30.43/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

23.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Equity 100
PEGY 0
FCF Margin 77
P/E (TTM) 0
Capex to Sales 75
OCF to Net Income 0

Technicals Bullish

99.0 / 100

Bullish setup leads (Stochastic Cross, MA Rejection, Fibonacci Retracement); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Stochastic Cross 88
MA Rejection 79
Fibonacci Retracement 76

Risk Gates

2 blocking 10 caution

2 guards active, 26 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ABBV.